Trial Profile
A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Granulocyte colony-stimulating factors; Granulocyte macrophage colony stimulating factor; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms ALEXANDRA; IMpassion030
- Sponsors Chugai Pharmaceutical; Roche
- 09 Dec 2023 Interim results presented at the 46th Annual San Antonio Breast Cancer Symposium.
- 20 Sep 2023 This trial has been discontinued in Italy (Date of the global end of the trial: 14-Aug-2023), according to the European Clinical Trials Database record.
- 16 Sep 2023 This trial has been Discontinued in Ireland.